<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mvjr</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский вестник Юга России</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Herald of the South of Russia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2219-8075</issn><issn pub-type="epub">2618-7876</issn><publisher><publisher-name>The Rostov State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21886/2219-8075-2019-10-4-71-79</article-id><article-id custom-type="elpub" pub-id-type="custom">mvjr-946</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Функциональные особенности врожденного иммунитета в развитии постперикардиотомного синдрома у пациентов после аортокоронарного шунтирования</article-title><trans-title-group xml:lang="en"><trans-title>Functional features of innate immunity in the development of postpericardiotomy syndrome in patients after coronary artery bypass grafting</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2193-7372</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шлык</surname><given-names>И. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Shlyk</surname><given-names>I. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., врач-кардиолог, докторант кафедры клинической иммунологии и аллергологии ФПК и ППС, </p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Cand. Sci. (Med.), doctoral candidate department of the allergology and immunology,</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">sushkina-83@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5716-4397</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сизякина</surname><given-names>Л. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Sizyakina</surname><given-names>L. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, заведующая кафедрой клинической иммунологии и аллергологии ФПК и ППС, </p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Dr. Sci. (Med.), professor, department of the allergology and immunology,</p><p>Rostov-on-Don</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8411-1554</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сидоров</surname><given-names>Р. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sidorov</surname><given-names>R. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., доцент кафедры хирургический болезней №2, </p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Dr. Sci. (Med.), associate Professor of the surgical diseases chair №2,</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">romas-64@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3070-8424</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шлык</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shlyk</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, заведующий кафедрой внутренних болезней № 4 ФПК и ППС, </p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Dr. Sci. (Med.), professor,</p><p>Rostov-on-Don</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Ростовский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Rostov State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>26</day><month>12</month><year>2019</year></pub-date><volume>10</volume><issue>4</issue><fpage>71</fpage><lpage>79</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Шлык И.Ф., Сизякина Л.П., Сидоров Р.В., Шлык С.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Шлык И.Ф., Сизякина Л.П., Сидоров Р.В., Шлык С.В.</copyright-holder><copyright-holder xml:lang="en">Shlyk I.F., Sizyakina L.P., Sidorov R.V., Shlyk S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.medicalherald.ru/jour/article/view/946">https://www.medicalherald.ru/jour/article/view/946</self-uri><abstract><sec><title>Цель</title><p>Цель: изучить функциональные особенности врожденного иммунитета в формировании постперикардиотомного синдрома (ППС) у пациентов, перенесших аортокоронарное шунтирование (АКШ).</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы: в исследовании приняли участие 60 человек (40 пациентов – с ИБС), которая ретроспективно через 1 месяц наблюдения была разделена на две группы. Группа I – АКШ и ППС, группа II – АКШ без ППС. Группу контроля составили 20 пациентов без ИБС. До операции, через 5, 14 суток и 1 месяц в клетках крови оценивали экспрессию толл подобных рецепторов (TLR)2,4,9, содержание лимфоцитов CD16+ и Гранзима В, НСТ тест и α-дефензин в сыворотке крови. Статистический анализ результатов исследования проводили с применением программы Statistica 12.0 (StatSoft , США). Различие средних величин между группами оценивали по критерию Манна-Уитни. Распределения величин и отличие от нормального анализировали по критерию Шапиро-Уилка. Статистическая значимость считалась достоверной при р ≤ 0,05.</p></sec><sec><title>Результаты</title><p>Результаты: при сравнении исходных показателей основных групп и группы контроля выявлены повышеие экспресии TLR 2, 4, 9, увеличение содержания СD16+, а также повышение цитотоксической активности натуральных киллеров и повышение продукции α-дефензина.</p></sec><sec><title>Выводы</title><p>Выводы: на основании проведенного исследования выявлена активация клеточного звена врожденного иммунитета, повышение цитотоксического потенциала натуральных киллеров и значимо высокий уровень α-дефензина, как до, так и после АКШ, что может играть важную роль в развитии ППС. </p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Objective</title><p>Objective: to study the functional characteristics of innate immunity in the formation of postpericardial syndrome (PPS) in patients undergoing coronary artery bypass graft ing (CABG).</p></sec><sec><title>Materials and methods</title><p>Materials and methods: the study involved 60 people, 40 of them made up the main group of patients with coronary artery disease, which retrospectively aft er 1 month of observation was divided into 2 groups. Group I CABG and PPS, group II CABG without PPS. The control group consisted of 20 patients without IHD. Before surgery, aft er 5, 14 days and 1 month, the expression of toll-like receptors (TLRs) 2, 4, 9, the content of CD16+ and Granzyme B lymphocytes, the HCT test and serum α-defensin were evaluated in blood cells. Statistical analysis of the results of the study was carried out using the program Statistica 12.0 (StatSoft , USA). The difference in mean values between groups was evaluated by the Mann-Whitney test. Statistical signifi cance was considered signifi cant at p ≤ 0.05.</p></sec><sec><title>Results</title><p>Results: when comparing the initial indices of the main groups and the control group, an increase in the expression of TLRs 2, 4, 9 was revealed. An increase in the content of CD16+, as well as an increase in the cytotoxic activity of natural killers and an increase in the production of α-defensin.</p></sec><sec><title>Conclusions</title><p>Conclusions: on the basis of the study, activation of the cellular link of innate immunity, an increase in the cytotoxic potential of natural killers and a signifi cantly high level of α-defensin both before and aft er CABG were revealed, which can play an important role in the development of PPS. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>аортокоронарное шунтирование</kwd><kwd>толл подобные рецепторы</kwd><kwd>врожденный иммунитет</kwd><kwd>постперикардиотомный синдром</kwd><kwd>α-дефензин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>coronary artery bypass grafting</kwd><kwd>toll-like receptors</kwd><kwd>innate immunity</kwd><kwd>postpericardiotomy syndrome</kwd><kwd>α-defensin</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">2014 ESC/EACTS Guidelines on myocardial revascularization. // European Heart Journal. - 2014. - №35. - С. 2541-2619.</mixed-citation><mixed-citation xml:lang="en">2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2014;35:2541-2619.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Imazio M., Belli R., Brucato A., Ferrazzi P., Patrini D., et al. Rationale and design of the Colchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative Atrial Fibrillation (COPPS-2 trial): a randomized, placebocontrolled, multicenter study on the use of colchicine for the primary prevention of the postpericardiotomy syndrome, postoperative eff usions, and postoperative atrial fibrillation. // Am. Heart J. - 2013. - №166. - С. 13-19. doi: 10.1016/j.ahj.2013.03.025</mixed-citation><mixed-citation xml:lang="en">Imazio, M, Belli R, Brucato A, Ferrazzi P, Patrini D, et al. Rationale and design of the Colchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative Atrial Fibrillation (COPPS-2 trial): a randomized, placebocontrolled, multicenter study on the use of colchicine for the primary prevention of the postpericardiotomy syndrome, postoperative effusions, and postoperative atrial fi brillation. Am. Heart J. 2013;166:13-19. doi: 10.1016/j.ahj.2013.03.025</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lehto J., Kiviniemi N., Gunn J., Airaksinen J., Rautava P., et. al. Occurrence of Postpericardiotomy Syndrome: Association With Operation Type and Postoperative Mortality Aft er Open-Heart Operations. // J Am Heart Assoc. - 2018. - №3. - С. e010269. doi: 10.1161/JAHA.118.010269</mixed-citation><mixed-citation xml:lang="en">Lehto J, Kiviniemi N, Gunn J, Airaksinen J, Rautava P, Kyto V, et. al. Occurrence of Postpericardiotomy Syndrome: Association With Operation Type and Postoperative Mortality Aft er Open-Heart Operations. J Am Heart Assoc. 2018;3:e010269. doi: 10.1161/JAHA.118.010269</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Gvaldin D.Y., Sidorov R.V., Milutina N.P., Shlyk S.V., Ananyan A.A. et. al. Funktioneller zusammenang zwischen myeloperoxidase und paraoxonase in den mechanismen der pathogenese des postperikardiotomie-syndroms bei patienten mit koronarer herzkrankheit und koronar-bypass. // Journal fur Kardiologie. - 2018. - T. 25 - №1-2. - С. 26-29.</mixed-citation><mixed-citation xml:lang="en">Gvaldin DY, Sidorov RV, Milutina NP, Shlyk SV, Ananyan AA, et. al. Funktioneller zusammenang zwischen myeloperoxidase und paraoxonase in den mechanismen der pathogenese des postperikardiotomie-syndroms bei patienten mit koronarer herzkrankheit und koronar-bypass. Journal fur Kardiologie. 2018;25(1-2):26-29.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Mott A.R., Fraser Jr. C.D., Kusnoor A.V., Giesecke N.M., Reul G.J. Jr, et al. The effect of short-term prophylactic methylprednisone on the incidence and severity of postpericardiotomy syndrome in children undergoing cardiac surgery with cardiopulmonary bypass. // J Am Coll Cardiol. - 2001. - №37. - С. 1700-1706. doi: 10.1016/s0735-1097(01)01223-2</mixed-citation><mixed-citation xml:lang="en">Mott AR, Fraser Jr CD, Kusnoor AV, Giesecke NM, Reul GJ Jr, et al. The effect of short-term prophylactic methylprednisone on the incidence and severity of postpericardiotomy syndrome in children undergoing cardiac surgery with cardiopulmonary bypass. J Am Coll Cardiol. 2001; 37:1700- 1706.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Horneffer P.J., Miller R.H., Pearson T.A., Rykiel M.F., Reitz B.A., Gardner T.J. The effective treatement of postcardiotomy syndrome after cardiac operations: a randomized placebocontrolled trial. // J Thorac Cardiovasc Surg. - 1990. - №100. - С. 292-296.</mixed-citation><mixed-citation xml:lang="en">Horneffer PJ, Miller RH, Pearson TA, Rykiel MF, Reitz BA, Gardner TJ. The effective treatement of postcardiotomy syndrome after cardiac operations: a randomized placebocontrolled trial. J Thorac Cardiovasc Surg. 1990;100:292-296.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Imazio M., Brucato A., Markel G., Cemin R., Trinchero R. et al. Meta-analysis of randomized trials focusing on prevention of the postpericardiotomy syndrome. // Am J Cardiol. - 2011. - №108. - С. 575-579. doi: 10.1016/j.amjcard.2011.03.087.</mixed-citation><mixed-citation xml:lang="en">Imazio M, Brucato A, Markel G, Cemin R, Trinchero R, et al. Meta-analysis of randomized trials focusing on prevention of the postpericardiotomy syndrome. Am J Cardiol. 2011;108:575-579. doi: 10.1016/j.amjcard.2011.03.087.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Imazio M., Brucato A., Rovere M.A., Gandino A., Cemin R., et. al. Contemporary Features, Risk Factors, and Prognosis of the PostPericardiotomy Syndrome. // Am J Cardiol. - 2011. - №108. - С. 1183-1187. doi: 10.1016/j.amjcard.2011.06.025</mixed-citation><mixed-citation xml:lang="en">Imazio M, Brucato A, Rovere MA, Gandino A, Cemin R, Ferrua S, et. al. Contemporary Features, Risk Factors, and Prognosis of the PostPericardiotomy Syndrome. Am J Cardiol. 2011;108:1183-1187. doi: 10.1016/j.amjcard.2011.06.025</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ayres J.S., Schneider D.S. Tolerance of infections. // Annu Rev Immunol. - 2012. - №30. - С. 271-294. doi: 10.1146/annurevimmunol-020711-075030</mixed-citation><mixed-citation xml:lang="en">Ayres JS, Schneider DS. Tolerance of infections. Annu Rev Immunol. 2012;30:271-294. doi:  10.1146/annurevimmunol-020711-075030</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Жидкова И.И., Понасенко А.В., Хуторная М.В., Кутихин А.Г., Барбараш О.Л. Генетические факторы (гены рецепторов врожденного иммунитета – TLRs) в патогенезе атеросклероза и его осложнений . // Медицинская иммунология. - 2017. - №3. - С. 241-254. doi: 10.15789/1563-0625-2017-3-241-254</mixed-citation><mixed-citation xml:lang="en">Zhidkova II, Ponasenko AV, Hutornaja MV, Kutihin AG, Barbarash OL. Genetic factors (innate immunity receptor genes - TLRs) in the pathogenesis of atherosclerosis and its complication. Medicinskaja immunologija. 2017;3:241-254. (In Russ) doi: 10.15789/1563-0625-2017-3-241-254.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Сизякина Л.П., Шлык И.Ф., Сидоров Р.В., Шлык С.В. Характеристика врожденного иммунитета в послеоперационном периоде у больных с аортокоронарным шунтированием. // Иммунология. - 2017. - №6. - С. 292-295.</mixed-citation><mixed-citation xml:lang="en">Sizjakina LP, Shlyk IF, Sidorov RV, Shlyk SV. Characterization of innate immunity in the postoperative period in patients with coronary artery bypass graft ing. Immunologija. 2017;6:292-295. (In Russ)</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Takeda K., Akira S. Toll-like receptors in innate immunity. // International Immunology. - 2005. - №1. - С. 1-14. doi: 10.1093/intimm/dxh186</mixed-citation><mixed-citation xml:lang="en">Takeda K, Akira S. Toll-like receptors in innate immunity. International Immunology. 2005;1:1-14. doi: 10.1093/intimm/dxh186</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Parisi L., Bassani B., Tremolati M., Gini E., Farronato G., Bruno A. Natural killer (NK) cells augment atherosclerosis by cytotoxic-dependent mechanisms. // Cardiovasc Res. - 2014. - №1. - С. 128-137. DOI: 10.1093/cvr/cvu016</mixed-citation><mixed-citation xml:lang="en">Parisi L, Bassani B, Tremolati M, Gini E, Farronato G, Bruno A. Natural killer (NK) cells augment atherosclerosis by cytotoxic-dependent mechanisms. Cardiovasc Res. 2014;1:128-137. doi: 10.1093/cvr/cvu016</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Saito Y., Kondo H., Hojo Y. Granzyme B as a novel factor involved in cardiovascular diseases. // Journal of Cardiology. - 2011. - №2. - С. 141-147. doi: 10.1016/j.jjcc.2010.10.001</mixed-citation><mixed-citation xml:lang="en">Saito Y, Kondo H, Hojo Y. Granzyme B as a novel factor involved in cardiovascular diseases. Journal of Cardiology. 2011;2:141-147. doi: 10.1016/j.jjcc.2010.10.001</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Мишланов В.Ю., Суханов С.Г., Сандаков П.Я., Ронзин А.В., Владимирский В.Е., и др. Дефензины-альфа, пептиды и белки, синтезируемые и высвобождаемые нейтрофилами при атеросклерозе разной локализации. // Клиническая лабораторная диагностика. - 2014. - №5. - С. 13-17.</mixed-citation><mixed-citation xml:lang="en">Mishlanov VJu, Suhanov SG, Sandakov PJa, Ronzin AV, Vladimirskiĭ VE, et al. Alpha defensins, peptides and proteins synthesized and released by neutrophils in atherosclerosis of different localization. Klinicheskaja laboratornaja diagnostika. 2014;5:13-17. (In Russ)</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Shintania Y., Kapoora A., Kanekoa M., Smolenski R.T., D’Acquistoa F.,et. al. TLR9 mediates cellular protection by modulating energy metabolism in cardiomyocytes and neurons. // Proceedings of the National Academy of Sciences. - 2013. - №13. - С. 5109-5114. doi: 10.1073/pnas.1219243110</mixed-citation><mixed-citation xml:lang="en">Shintania Y, Kapoora A, Kanekoa M, Smolenski RT, D’Acquistoa F, Coppena SR, et. al. TLR9 mediates cellular protection by modulating energy metabolism in cardiomyocytes and neurons. Proceedings of the National Academy of Sciences. 2013;13:5109-5114. doi: 10.1073/pnas.1219243110</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Gorla R., Erbel R., Eagle K. A., Bossone E. Systemic inflammatory response syndromes in the era of interventional cardiology. // Vascular Pharmacology. - 2018. - №107. - С. 53-66. doi: 10.1016/j.vph.2018.04.003</mixed-citation><mixed-citation xml:lang="en">Gorla R, Erbel R, Eagle KA, Bossone E. Systemic inflammatory response syndromes in the era of interventional cardiology. Vascular Pharmacology. 2018;107:53-66. doi: 10.1016/j.vph.2018.04.003</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
